Bio-Rad Laboratories, Inc. Class A Common Stock vs HSBC Holdings plc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.02B), while HSBC Holdings plc trades at $99.51 (market cap $330.96B). The key difference: HSBC Holdings plc is far larger — about 41.3× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and HSBC Holdings plc pays a 3.82% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | HSBC | |
|---|---|---|
Market Cap | $8.02B | $330.96B |
Sector | Health | Technology |
52-Week High | $339.75 | $99.25 |
52-Week Low | $241.71 | $61.30 |
Enterprise Value | $7.84B | — |
Dividend Yield | — | 3.82% |
Trailing returns across standard periods
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →